These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33348988)

  • 1. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
    Shinn LT; Vo KA; Reeves DJ
    Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurbinectedin in the treatment of relapsed small cell lung cancer.
    Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
    Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
    Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
    Badin F
    Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
    Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
    Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
    Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T
    Intern Med J; 2024 Jul; 54(7):1087-1096. PubMed ID: 38369719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
    Patel S; Petty WJ; Sands JM
    Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
    Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
    Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
    Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
    Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
    Rajput PS; Khan SR; Singh P; Chawla PA
    Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
    Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
    Meyer H; Sunkara R; Rothmann E; Shah A; Riaz I; Courtney KD; Armstrong AJ; Lippucci A; Naqvi SAA; Stanton ML; Beltran H; Bryce AH
    Clin Genitourin Cancer; 2024 Oct; 22(5):102172. PubMed ID: 39232269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
    Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
    Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas.
    Khoury R; Assi T; Ibrahim R; Ibrahim T; Verret B; Henon C; Bahleda R; Le Cesne A
    Curr Treat Options Oncol; 2024 Feb; 25(2):176-190. PubMed ID: 38324075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.